title: Why are cytokines targeted for biological therapy in IBD?
authors.affiliation: Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, California, USA.
authors.forename: Masayuki
authors.initials: M
authors.lastname: Saruta
authors.forename: Konstantinos A
authors.initials: KA
authors.lastname: Papadakis
mesh_terms: D001688:Biological Products / Q000627:therapeutic use; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D018928:Immunity, Mucosal; D007167:Immunotherapy; D015212:Inflammatory Bowel Diseases / Q000276:immunology* / Q000378:metabolism / Q000628:therapy*
chemical_list: D001688:Biological Products; D016207:Cytokines